Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents (Q47294633)

13 January 2018

title

Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents (English)

1 reference

13 January 2018

1 reference

2

1 reference

13 January 2018

author name string

Chang-Heok Soh

1

1 reference

13 January 2018

Michael T Brady

3

1 reference

13 January 2018

Stephen A Spector

4

1 reference

13 January 2018

William Borkowsky

5

1 reference

13 January 2018

Sandra K Burchett

6

1 reference

13 January 2018

Marc D Foca

7

1 reference

13 January 2018

Edward Handelsman

8

1 reference

13 January 2018

Eleanor Jiménez

9

1 reference

13 January 2018

Wayne M Dankner

10

1 reference

13 January 2018

Michael D Hughes

11

1 reference

13 January 2018

Pediatric AIDS Clinical Trials Group

12

1 reference

13 January 2018

language of work or name

English

0 references

publication date

1 December 2003

1 reference

13 January 2018

published in

The Lancet

1 reference

13 January 2018

volume

362

1 reference

13 January 2018

issue

9401

1 reference

13 January 2018

page(s)

2045-2051

1 reference

13 January 2018

PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

A phase I/II study of the protease inhibitor indinavir in children with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Protease inhibitor therapy in children with perinatally acquired HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Combination Nucleoside Analog Reverse Transcriptase Inhibitor(s) Plus Nevirapine, Nelfinavir, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: Week 24 Results of a Randomized Controlled Trial - PACTG 377

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Random-effects models for longitudinal data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

The CCR5Delta32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915098-2

7 January 2021

10.1016/S0140-6736(03)15098-2

Identifiers

DOI

1 reference

13 January 2018

PubMed ID

14697803

1 reference

13 January 2018